Advancing Radioligand Therapy Development Through Robust Preclinical and Translational Tools

Webinar

Discover how informed early-stage decisions in preclinical modeling, radiochemistry, and study design accelerate radioligand therapy pipelines.

Radioligand therapy development is progressing rapidly, but success depends on selecting the right preclinical models, optimal study designs and translational strategies. Many programs stall due to gaps in model relevance, study design or isotopic selection.

Watch this webinar to explore how early, informed decisions can de-risk development, validate therapeutic targets and support clinical translation, from discovery through IND.

This webinar is designed for researchers, drug developers and translational scientists focused on radioligand therapy and other targeted therapeutic approaches.

It will highlight how the integration of radiochemistry, robust preclinical models and well-designed studies can generate reliable and reproducible data to guide smarter development decisions.

Join the featured speakers to explore:

• How to choose preclinical tumor models that reflect relevant biology and target expression
• Radiochemistry considerations, including isotope selection and labeling strategies
• Best practices for designing preclinical studies that address key translational questions
• How to generate decision-ready data that supports clinical translation
• A case study from glioblastoma research, showing how a combination of FACs analysis and advanced [¹⁷⁷Lu]FAP-2886 imaging can be used to determine FAP targeting and therapeutic potential in the U87MG model